布林佐胺 1%/噻吗洛尔 0.5%：一种新型青光眼固定联合降眼压产品的安全性和疗效。
Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.
机构信息
Eye Clinic, Kaunas University of Medicine, Kaunas, Lithuania.
出版信息
Curr Med Res Opin. 2010 Nov;26(11):2575-8. doi: 10.1185/03007995.2010.517718. Epub 2010 Sep 27.
OBJECTIVE
To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1%/timolol 0.5%.
METHODS
Medline was searched for brinzolamide/timolol fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide/timolol literature was reviewed.
RESULTS
Compared with another carbonic anhydrase inhibitor-containing product, dorzolamide 2%/timolol 0.5%, brinzolamide/timolol has similar IOP-lowering efficacy. Brinzolamide/timolol also produces superior comfort ratings as assessed by patients who have tried both drugs - this may be explained by the more physiologic pH of brinzolamide/timolol. A recent study reported that brinzolamide/timolol was preferred over dorzolamide/timolol at a ratio of nearly 4:1 among those expressing a preference.
CONCLUSION
These results demonstrate that brinzolamide/timolol is equally effective and more comfortable than dorzolamide/timolol, a fact that may positively impact patient adherence, leading to an increased likelihood of reaching target IOP goals.
目的
对新型降眼压固定复方制剂布林佐胺 1%/噻吗洛尔 0.5%的近期研究进行述评。
方法
检索 Medline 上布林佐胺/噻吗洛尔固定复方制剂临床文献（截至 2010 年 5 月 18 日）并对当前的布林佐胺/噻吗洛尔全面文献进行了回顾。
结果
与另一种含有碳酸酐酶抑制剂的药物多佐胺 2%/噻吗洛尔 0.5%相比，布林佐胺/噻吗洛尔具有相似的降眼压疗效。患者在尝试了这两种药物后，认为布林佐胺/噻吗洛尔具有更好的舒适度评分 - 这可能是由于布林佐胺/噻吗洛尔具有更接近生理的 pH 值。最近的一项研究报告称，在表达偏好的患者中，布林佐胺/噻吗洛尔的偏好率接近 4:1，优于多佐胺/噻吗洛尔。
结论
这些结果表明，布林佐胺/噻吗洛尔与多佐胺/噻吗洛尔同样有效，且舒适度更高，这一事实可能会对患者的依从性产生积极影响，从而增加达到目标眼压的可能性。
Zotero 插件